Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient

a technology of cordyceps and mycellia, which is applied in the direction of drug compositions, immunological disorders, antibody medical ingredients, etc., can solve the problems of side effects of this drug, and the use of vegetable worm extracts as immunosuppressants has not been disclosed in the prior period, so as to suppress the production of antibodies and arrest the oozing of sores

Inactive Publication Date: 2010-11-18
HANKOOK PHARM
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]The cordyceps mycellia extract was found to significantly suppress the production of antibodies to transplants without side effects, such as weight change. Based on a natural material, the composition is non-toxic and harmless to the human body, and thus can be used as an immunosuppressant for organ transplantation. Also, it arrests oozing from sores and is applicable to the prevention and treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, pemphigus and smallpox.

Problems solved by technology

However, side effects of this drug have also been found (Clin.
However, nowhere has the use of vegetable worm extracts as an immunosuppressant been disclosed in the prior art.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient
  • Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient
  • Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient

Examples

Experimental program
Comparison scheme
Effect test

example 1

Immunosuppression Assay on Pemphigus Mouse Model

[0039]An immunosuppression test was conducted with the cordyceps mycellia extract of the present invention on pemphigus mouse models, as follows.

[0040]Two S129 Dsg3− / − mice and 24 S129 Rag2− / − mice were prepared as transplantation donors and recipients, respectively. The recipient mice were divided into four groups of six: control (CMC administered), comparative group (cyclophosphamide (CPA) administered), experimental group 1 and experimental group 2 (cordyceps mycellia extract (Cordyma®; Han Kook Sin Yak) administered). The transplantation donor was subjected to an immune reaction by administering a Dsg3-His protein thereto, as described below. First, 10 μg of mouse Dsg3-His protein was emulsified with the same amount of complete Freund's adjuvant (CFA) and subcutaneously injected into the mice (1st). One week after the first immunization, an emulsion of 10 μg of mouse Dsg3-His protein in the same amount of incomplete Freund's adjuva...

preparation example 1

Preparation of Pharmaceutical Formulations

[0051]1-1. Preparation of Powder

Cordyceps mycellia extract  1 gDextrin0.1 g

[0052]The above ingredients were mixed and loaded into an airtight sac to produce powder.

[0053]1-2. Preparation of Tablet

Cordyceps mycellia extract500 mgDextrin 45 mgMg Stearate 5 mg

[0054]These ingredients were mixed and prepared into tablets using a typical tabletting method.

[0055]1-3. Preparation of Capsule

Cordyceps mycellia extract500 mgDextrin 50 mg

[0056]These ingredients were mixed and loaded into gelatin capsules according to a typical method to produce capsules.

[0057]1-4. Preparation of Injection

Cordyceps mycellia extract50mg / mlDiluted HCl BPadded to form pH 3.5NaCl BP injectionup to 1ml

[0058]The cordyceps mycellia extract was dissolved in a suitable volume of an NaCl BP injection, and the solution was adjusted to a pH of 3.5 with diluted HCl BP and to a desired volume with NaCl BP injection, followed by sufficient mixing. The solution was loaded into transpare...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
total volumeaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a cordyceps mycellia extract as an active ingredient. The cordyceps mycellia extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material, the composition is non-toxic and harmless to the human body and thus can be used as an immunosuppressant for organ transplantation. Also, it stops oozing from sores and is useful in the prevention and treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, pemphigus and smallpox.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for inhibition of transplant rejection, comprising a cordyceps mycellia extract as an active ingredient.BACKGROUND ART[0002]Transplant rejection occurs when the immune system of the recipient of a transplant attacks a transplanted organ or tissue. Thus, effective suppression of the immune response is known as a main factor determining the success of transplantation. In this regard, the development of immunosuppressive medications has brought about exceptional advances in the transplantation of organs and tissues and the treatment of autoimmune diseases and has made a great contribution to the study of the in vivo mechanism of immune responses to the transplanted organ or tissue.[0003]As described, immunosuppressive drugs were developed to inhibit or attenuate transplant rejection. An example is cyclosporine A (U.S. Pat. No. 4,117,118) produced from Tolypocladium inflatum, a soil fungus. These immunosuppressive drugs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/068A61K36/06A61P37/06A61P17/00A61P17/02A61P31/20
CPCA61K36/068A61P17/00A61P17/02A61P31/20A61P37/00A61P37/06A61P37/08
Inventor HAN, MAN WOOYOO, JAE KUKHUR, CHANG-UKKIM, HWAN-CHULKIM, JIN PYO
Owner HANKOOK PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap